White & Case assists Takeda with LatAm business divestment
White & Case has assisted Takeda Pharmaceutical Company Limited with its agreement to divest a portfolio of select over-the-counter and prescription pharmaceutical products in Latin American countries, within its Growth and Emerging Markets Business Unit, to Hypera Pharma.
The transaction is valued at $825 million.
Takeda is a global biopharmaceutical leader headquartered in Japan, while Hypera Pharma is Brazil’s largest pharmaceutical company with a leading position in branded prescriptions, consumer health and branded generics.
The White & Case team which advised on the transaction was led by partners Michael Immordino (pictured) and Leonardo Graffi (both Milan and London).
The team also included partners Philip Trillmich, Monica Holden, Dominic Ross, Martin Forbes and Gilles Teerlink (all London), Arlene Hahn and David Dreier (both New York) and Axel Schulz (Brussels), counsel Isaac Tendler (New York) and associates Andrea Pretti, Fabrizia Faggiano and Alessandro Piga (all Milan), Ajita Shukla (Washington, DC), Kyle Oh (Seoul and Singapore), Mariana Seixas (San Paulo), Benjamin Snow (New York), Tommaso Poli (Brussels) and lawyer Mariasole Maschio (Milan).
